Serum IL-6, TNFα and CRP levels in Greek colorectal cancer patients: Prognostic implications

Nikiteas, Nikolaos; Tzanakis, Νikolaos; Gazouli, Maria; Rallis, George; Daniilidis, Kessaris; Theodoropoulos, George; Kostakis, Alkiviadis; Peros, George

doi:10.3748/wjg.v11.i11.1639

Cited by 136 publications

(120 citation statements)

References 23 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, a number of studies carried out in primary operable colo-rectal cancer have highlighted the independent prognostic value of an elevated C-reactive protein concentration (55)(56)(57)(58)(59)(60)(61)(62) , with only two studies failing to observe such a relationship (63,64) . Recently, the prognostic value of the GPS has been examined in patients with either primary operable colorectal cancer (n 149) or synchronous unresectable liver metastases (n 84) (65) .…”

Section: Application Of a Systemic-inflammation-based Score In Patienmentioning

confidence: 99%

“…McMillan et al (55) Colo-rectal 36 Post-op CRP stage independent Nozoe et al (56) Colo-rectal 120 Pre-op CRP stage independent Nielsen et al (57) Colo-rectal 456 Pre-op CRP stage independent Wigmore et al (63) Colo-rectal 202 Pre-and post-op CRP not stage independent McMillan et al (58) Colo-rectal 174 Pre-and post-op CRP stage independent Chung et al (64) Colo-rectal 172 Pre-op CRP not stage independent Nikiteas et al (59) Colo-rectal 74 Pre-op CRP stage independent Crozier et al (60) Colo-rectal 222 Pre-op CRP stage and treatment independent Wong et al …”

Section: Application Of a Systemic-inflammation-based Score In Patienmentioning

confidence: 99%

See 1 more Smart Citation

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

2008

View full text Add to dashboard Cite

Progressive involuntary weight loss, in particular the loss of lean tissue, is common in patients with advanced cancer and has long been recognised to result in a deterioration in performance status and quality of life, increased morbidity and mortality. The aetiology of such weight loss or cachexia is complex and involves both tumour and host responses. Thus, identification of patients who are or are likely to become cachectic has been problematic. In addition to a reduction in appetite and increased satiety leading to poor dietary intake, there is now increasing clinical evidence that the activation of a chronic ongoing systemic inflammatory response is one of the earliest and most important contributory factors to cachexia. Such findings help to explain the failure of simple nutritional programmes to reverse weight loss adequately in patients with cancer. In the present paper the development of an inflammationbased score is described, which is derived from the acute-phase proteins C-reactive protein and albumin and is termed the Glasgow prognostic score (GPS). Its value as a predictor of survival, independent of tumour stage, performance status and treatment (active or palliative), has been shown in a variety of advanced common solid tumours. The nature of the relationship between the GPS, appetite, body composition, performance status and quality of life of the patient with advanced cancer will be described. Recently, it has become evident that the systemic inflammatory response is also present in a smaller proportion of patients with primary operable cancer and is also predictive of disease progression and poor survival. The role of GPS in clinical decision making will be discussed.

show abstract

Section: Application Of a Systemic-inflammation-based Score In Patienmentioning

confidence: 99%

Section: Application Of a Systemic-inflammation-based Score In Patienmentioning

confidence: 99%

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

2008

View full text Add to dashboard Cite

show abstract

“…Moreover, a Greek study demonstrated that high levels of serum IL-6, TNF-α and CRP were correlated with larger tumor size. The relation to tumor size could be related to the fact, that larger tumors may trigger a more potent immunological response manifested by the circulation of proinflammatory cytokines such as TNF-α [56] . PPAR-γ PPAR-γ, a ligand-activated transcription factor, is a key regulator of adipogenic differentiation and glucose homeostasis.…”

Section: Inflammatory Cytokines and Colorectal Cancermentioning

confidence: 99%

Metabolic syndrome and risk of subsequent colorectal cancer

Pais¹,

Silaghi²,

Silaghi³

et al. 2009

WJG

153

145

View full text Add to dashboard Cite

The metabolic syndrome and visceral obesity have an increasing prevalence and incidence in the general population. The actual prevalence of the metabolic syndrome is 24% in US population and between 24.6% and 30.9% in Europe. As demonstrated by many clinical trials (NAHANES Ⅲ, INTERHART) the metabolic syndrome is associated with an increased risk of both diabetes and cardiovascular disease. In addition to cardiovascular disease, individual components of the metabolic syndrome have been linked to the development of cancer, particularly to colorectal cancer. Colorectal cancer is an important public health problem; in the year 2000 there was an estimated total of 944 717 incident cases of colorectal cancer diagnosed world-wide. This association is sustained by many epidemiological studies. Recent reports suggest that individuals with metabolic syndrome have a higher risk of colon or rectal cancer. Moreover, the clusters of metabolic syndrome components increase the risk of associated cancer. The physiopathological mechanism that links metabolic syndrome and colorectal cancer is mostly related to abdominal obesity and insulin resistance. Population and experimental studies demonstrated that hyperinsulinemia, elevated C-peptide, elevated body mass index, high levels of insulin growth factor-1, low levels of insulin growth factor binding protein-3, high leptin levels and low adiponectin levels are all involved in carcinogenesis. Understanding the pathological mechanism that links metabolic syndrome and its components to carcinogenesis has a major clinical significance and may have profound health benefits on a number of diseases including cancer, which represents a major cause of mortality and morbidity in our societies.

show abstract

“…Chez l'homme, il a été montré qu'elle pouvait bloquer la maturation des cellules dendritiques [33]. De plus, le niveau d'IL-6 présent dans le sérum de patients atteints de cancer colorectal a été associé avec la taille de la tumeur, la progression tumorale, ainsi qu'avec une survie plus courte [34]. L'IL-1 a comme sources principales les macrophages et les cellules dendritiques.…”

Section: La Prostaglandine E2 (Pge2)unclassified

Microenvironnement tumoral

Bruchard

Ghiringhelli

2014

Med Sci (Paris)

View full text Add to dashboard Cite

Serum IL-6, TNFα and CRP levels in Greek colorectal cancer patients: Prognostic implications

Cited by 136 publications

References 23 publications

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

Metabolic syndrome and risk of subsequent colorectal cancer

Microenvironnement tumoral

Contact Info

Product

Resources

About